It can therefore be hypothesized that treatment with a combination of metyrapone and a potent MR antagonist such as finerenone, spironolactone, or eplerenone [25] may be able to achieve a significant reduction in Cushing’s Syndrome-associated atherosclerosis susceptibility. Here, NR3C2 is linked to atherosclerosis.